LY4268989 (MORF-057)

LY4268989 · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LY4268989 (MORF-057), covering 2026-03-27 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: [Phase 2]

See pricing